ERBB2 and breast carcinoma: Recent clinical trials have demonstrated that patients with HER2-positive breast cancer as well as patients with HER2-low breast cancer exhibit high response rates to HER2-targeted antibody drug conjugates, such as trastuzumab (DS-8201) (12, 13).